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Background: There are only few studies on cancer patients who are treated in complementary and alternative
medicine clinics and comparing them with patients in conventional care. We will present the comparison of
characteristics of two patient cohorts: one was treated in a homeopathic cancer care clinic and one was treated in
a conventional oncology care (CC) outpatient clinic.
Patients and methods: Six-hundred and forty-seven patients were included in this cross-sectional cohort study
and had to fill in questionnaires [health-related quality of life (QoL) (Functional Assessment of Cancer
Therapy—General Scale), depression and anxiety (Hospital Anxiety and Depression Scale), fatigue (Multidimensional
Fatigue Inventory) and expectancies toward treatment]. Clinical data were extracted from medical records. This study
presents the comparison of both cohorts.
Results: Patients in the homeopathy cohort are younger, better educated and more often employed than patients in
the CC cohort. The most pronounced differences indicate longer disease histories and different diagnostic and clinical
pretreatment variables. Despite the clinical differences, QoL as well as anxiety, depression and fatigue was similar in
both the groups.
Conclusions: Homeopathic treatment is sought by cancer patients at a different phase during the course of the
disease, which has particular implications for research. However, expectancies toward the benefit of the treatment as
well as QoL data are similar.
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introduction
Homeopathy is one of the most popular approaches in
complementary and alternative medicine (CAM) in cancer care
in Europe ranging from 6% across cancer diagnoses [1, 2] up to
24% in breast cancer patients [3–5]. Homeopathy is
a comprehensive CAM system which is based upon a theory
and practice which has evolved independent from conventional
medicine.
In a review summarizing randomised, controlled trials on
homeopathic treatment in cancer patients, the authors
concluded that homeopathy may mitigate the side-effects of
chemotherapy and radiotherapy, resulting in improved quality of
life (QoL), especially in breast cancer patients [6]. The usefulness
of homeopathy as supportive care strategy is further
corroborated by a prospective observational study which
demonstrated that homeopathy had a positive influence on QoL
(as measured by the European Organisation for Research and
Treatment of Cancer-Quality of Life Questionnaire-30 items) as
well as on fatigue and hot flushes [7]. Results from basic research
looking at the effects of homeopathic dilutions on the progression
of cancer show conflicting results: Jonas et al. [8] found that both
the number and the volume of prostate tumors in rats decreased
after homeopathic treatment in an initial study but was unable to
replicate that in subsequent attempts [9–11] found no measurable
effects in cancer cell and animal models in basic research.
In light of the high prevalence of CAM approaches in cancer
treatment, it is worthwhile to investigate what type of patients
turn to CAM treatment and why. We studied patients from
a homeopathic clinic specialized in oncology and compared the
results with a cohort of cancer patients recruited at the same
time period from a conventional oncology outpatient clinic. A
similarly designed controlled registration study in Switzerland
showed that more patients in the CAM cohort (anthroposophic
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medicine) were female, higher educated and from an urban
environment. Patients in the CAM cohort also had poorer
performance status and a longer disease history since first
diagnosis [12]. Typical sociodemographic characteristics of
cancer patients treated with CAM are: female, well educated and
younger [13–17]. Clinical variables which predict CAM use are
advanced disease status [18] and a multitude of anticancer
treatments [14]. Some studies investigated CAM use and the
association with the cancer treatment phase. They found that in
the initial phase after diagnosis, the most frequent users of CAM
are breast cancer patients, whereas in a later phase of the disease,
lung cancer patients were identified as the most frequent users
[2]. Therefore, it could be assumed that CAM use and probably
also the expectancies attached to it depend not only on the cancer
type but also on the course of the disease.
Often-cited reasons of CAM use is boosting general health
and well-being rather than the hope of curing the cancer [14,
19]. CAM users are known to have worse QoL health status
than nonusers [17, 20]. There are conflicting results regarding
the question if patients who are unsatisfied with conventional
oncology care (CC) are more likely to turn to CAM [21, 22].
This cross-sectional study on characteristics of cancer
patients using homeopathy was part of a larger longitudinal
cohort study investigating both the questions who turns to
homeopathy and what is the course of the disease when
compared with patients who stay in conventional care. The
objective of the study presented here was to describe patient
cohorts and disease variables of cancer patients who begin
classical homeopathy compared with cancer patients who begin
conventional treatment.
patients and methods
recruitment
From 2004 to 2007, we recruited 647 cancer patients for a prospective study
with several cross-sectional and longitudinal research questions. Patients
were entered into the study consecutively when presenting at a homeopathic
or a conventional outpatient clinic for the first time. No specific inclusion and
exclusion criteria were imposed as one of the cross-sectional research
questions was the comparison of the two groups (presented here). One cohort
represents the cancer patient group that seeks treatment at a specialized
homeopathic clinic in Switzerland (founded by Spinedi in Orselina,
Switzerland, referred to as HOM). The other cohort was the usual cancer
patient group receiving treatment at a conventional outpatient oncology unit
which applies state-of-the-art diagnosis and treatment. It was originally
intended to recruit four potential matching partners in the group receiving
conventional care to compare with one patient treated with homeopathy.
Therefore, we recruited more conventionally treated patients than patients
treated with homeopathy but failed to reach the initial recruitment goal due
to recruitment problems in the conventional care clinic.
Informed consent was sought through the doctors but it was pointed out to
the patients that the questionnaire will go directly to the study center and will
not be seen by the respective doctors. Thus, anonymity of answers was
guaranteed. Anonymity was also ensured during data entry and analysis. The
study was approved by the Ethics Committee of the University Freiburg,
Germany as well as the Ethics Committee, Bellinzona, Switzerland.
the overall study
A longitudinal cohort study documented the course of the disease in
homeopathic and in conventionally treated patients over a follow-up period
of 12 months per cohort and sought to compare treatment outcomes in
subgroups after a well-defined matching process (data not shown here). Two
types of data were collected; we extracted data from medical records and
sent out questionnaires to the patients at baseline, 3, 6, 9 and 12 months after
the initial interview. Via medical records we collected disease variables like
cancer type, cancer stage, time since first diagnosis and time since progress
of disease and treatment variables like frequency of the courses of
chemotherapy and radiotherapy, surgery, etc. As the comprehensiveness of
medical records differed widely between the CC and the homeopathic clinic,
we made every effort to get medical records from homeopathic patients
through their conventional doctors or hospital admissions.
The patient surveys contained validated questionnaires measuring QoL
(Functional Assessment of Cancer Therapy—General Scale, FACT-G and
Functional Assessment of Chronic Illness Therapy—Spiritual Scale, FACIT-Sp
[23]), anxiety and depression [Hospital Anxiety and Depression Scale (HADS)
[24]], fatigue [Multidimensional Fatigue Inventory (MFI) [25]] and expectancies
(baseline measurement) as well as satisfaction with treatment (not at baseline).
We employed Access 2000 to store and SPSS 15.0 to analyze the data.
this study
We will report on the baseline data, i.e. extracted from questionnaires and
from medical records. Comparisons of both the groups are being made in
order to get more insight into cancer patients treated with homeopathy
compared with CC cancer patients and to inform the matching process later
employed in the overall study. We follow the STROBE (STrengthening the
Reporting of OBservational studies in Epidemiology) guidelines on
reporting results of observational studies [26].
statistical analysis
As this is the comparison of baseline characteristics of the two patient
groups, we employed unpaired 2-sample t-test to test for differences
whenever appropriate. In case of nominal data chi-square tests and in case
of ordinal data Wilcoxon tests were carried out. Measures used are
indicated in the tables.
results
patient characteristics
Figure 1 shows the number of patients included into this
analysis. The HOM cohort comprises 259 patients and the CC
cohort 380 cancer patients. As there were eight patients who
were recruited into the study but provided no questionnaires or
medical data, we excluded them from further analysis. We
achieved a return rate of questionnaires of 97% of all 259
homeopathy patients and 82% of all 380 CC patients. We were
able to collect 100% of the medical records of CC patients and
93% of the records of homeopathy patients.
comparison of baseline data
Table 1 summarizes sociodemographic data which show the
most pronounced differences in relation to age (HOM patients
are on average 6 years younger) and to education. A
significantly greater percentage of homeopathy patients had
higher education leading to a university degree. Another
significant difference was found in employment status with
more homeopathy patients being (still) employed. This may
also be a result of more self-employment in the homeopathy
group (data not shown). Both the groups had higher rates of
female patients, but there is no difference between the groups.
Annals of Oncology original article
Volume 21 | No. 5 | May 2010 doi:10.1093/annonc/mdp421 | 1095
Table 2 illustrates important clinical data at the time of
cancer diagnosis. In both the groups, the largest subgroup
consists of breast cancer patients (32% in HOM and 37% in CC
cohort). In terms of differences between the groups, it has to be
noted that in the CC cohort, there are about two times as many
colorectal cancer patients compared with HOM (15% versus
7%) and more melanoma patients in the HOM cohort (5%
versus 1%). The most significant difference though is the tumor
stage: in 27% of the HOM cohort patients, there was no
unequivocal tumor stage present because results from some
relevant diagnostic procedures were not available or had not
been even carried out versus 10% in the CC cohort; 4% of the
HOM cohort patients had refused any diagnostic examination
versus 0.5% in the CC cohort.
In addition to the lack of precise diagnostic procedures, there
were also differences with respect to conventional treatment. In
the HOM cohort, 86% of patients had conventional treatment
in comparison with the CC cohort: 95.5% had conventional
treatment in the past or are in the process of realization; 8% of
the HOM cohort refused conventional therapy before seeking
homeopathic treatment. Those HOM patients who received
conventional treatment were significantly more often treated
with chemotherapy and/or radiotherapy. There was no
difference in the amount of unconventional strategies except
vitamins (data drawn from patient questionnaire). Vitamins
were significantly more often used by HOM patients (Table 3).
Table 4 illustrates the disease variables at the time of study
entry, i.e. the time when patients started either homeopathic
treatment or conventional treatment in the usual care oncology
clinic. At the time of study entry, the differences between the
two groups were even more pronounced compared with the
time of the first diagnosis. HOM patients had been ill for
a longer time and were significantly less likely to be in a curative
disease stage. In addition, the percentage of HOM patients
whose tumor stage remained unclear was substantial (18%
compared with 7% CC patients).
Figure 1. Flowchart of records and questionnaires.
Table 1. Sociodemographics
HOM,
N = 250
Conventional
care, N = 310
P
values
Gender, N (%a)
Female 177 (70.8) 199 (64.8) n.s.b
Age
Mean (SD) 53.8 (12.6) 59.9 (12.0) 0.000c
Marital status, N (%a)
Married/with partner 174 (69.6) 226 (73.6)
Single/without partner 76 (30.4) 81 (26.3) n.s.b
Education, N (%)
Elementary school 40 (16.1) 147 (47.7)
Lower secondary 67 (27.0) 76 (24.7) 0.000b
Upper secondary 134 (54.0) 78 (25.3)
Highest degree, N (%)
University 107 (43.0) 49 (16.2) 0.000b
Other 142 (57.0) 254 (83.8)
Employment status, N (%)
Yes 75 (30.6) 47 (15.5)
No 171 (69.8) 256 (84.6) 0.000b
aPercentages refer to valid data (excluding missing data).
bChi-square test, one-sided.
ct-test, one-sided.
HOM, homeopathy; SD, standard deviation; n.s., not significant.
Table 2. Clinical variables at the time of the first diagnosis
HOM,
N = 243
Conventional
care, N = 380
P
values
Type of cancer, N (%)
Breast 77 (31.8) 140 (36.8) n.s.a
Prostate 18 (7.4) 13 (3.4) n.s.a
Colorectal 16 (6.6) 57 (15.0) 0.0005a
Melanoma 13 (5.4) 5 (1.3) 0.0003a
Other 118 (48.8) 165 (43.4)
Tumor stage, N (%)
Stage 1–3 123 (50.6) 237 (62.4)
Stage 4 55 (22.6) 103 (27.1) 0.000a
Unclear 65 (26.7) 40 (10.5)
aChi-square test, one-sided.
HOM, homeopathy; n.s., not significant.
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Table 5 summarizes the results of QoL measurements,
depression and anxiety and fatigue measures collected with the
baseline questionnaire.
There were striking similarities between both the groups with
regard to subjective well-being. Both the groups score rather
low with respect to their subjective QoL and anxiety and
depression compared with historical controls [27–30].
Regarding what patients expect from homeopathic or from
conventional anticancer treatment, it became obvious that there
were very similar expectancies in both the groups (see Table 6).
Despite some statistical significant differences, we do not
interpret these as being clinically relevant and therefore conclude
from our data that even the expectancies for homeopathic
treatment as anticancer strategy are comparable to the
expectancies of patients who received conventional treatment.
Additionally, a very high percentage of homeopathy patients also
hoped that homeopathy would be able to diminish adverse effects
of conventional treatment (88%, data not shown).
discussion
The objective of this study was to investigate whether cancer
patients recruited from a specialized homeopathy clinic were
Table 3. Course of the treatment since first diagnosis
HOM,
N = 243
Conventional
care, N = 380
P
values
Conventional therapy, N (%)
Yes 210 (86.4) 363 (95.5) 0.000a
No treatment indicated 4 (1.7) 11 (2.9)
Patient declined 21 (7.7) 4 (1.1)
Which therapies? N (%)
Operation 169 (69.4) 270 (71.1) n.s.a
Chemotherapy 122 (50.0) 124 (32.6) 0.000a
Radiotherapy 78 (32.2) 72 (18.9) 0.000a
Hormonotherapy 35 (14.5) 51 (13.4) n.s.a
Unconventional therapyb, N (%)
Mistletoe 32 (12.8) 40 (12.9) n.s.a
Vitamins 92 (36.8) 62 (20.1) 0.000a
Herbal medicine 38 (15.2) 50 (16.2) n.s.a
Enzymes 14 (5.6) 14 (4.5) n.s.a
aChi-square test, one-sided.
bDrawn from patients’ questionnaire (HOM: N = 250, CC: N = 310) as in
medical records CAM therapies were noted very rarely.
HOM, homeopathy; n.s., not significant; CAM, complementary and
alternative medicine.
Table 4. Disease variables at the time of study entry (in months)
HOM Conventional
care
P
values
Time since first diagnosis
(median, all patients)
10 (N = 243) 3 (N = 380) 0.000a
Time from first diagnosis to
tumor progress (median, only
patients with tumor progress)
34.5 (N = 76) 23 (N = 100) n.s.a
Time from tumor progress to
study entry (median, only
patients with tumor progress)
7 (N = 77) 3 (N = 101) 0.0004a
Tumor stage, N (%)
Stage 1–3 69 (29.9) 161 (43.1)
Not curative 121 (52.4) 187 (50.0) 0.000b
Unclear 41 (17.7) 26 (7.0)
aMann–Whitney U test, one-sided.
bChi-square test, one-sided.
HOM, homeopathy; n.s., not significant.
Table 5. Quality of life, depression, anxiety and fatigue
HOM,
N = 250
Conventional
care, N = 310
P
values
Historical
controls
FACT-G, mean (SD) 74.2 (14.8) 74.2 (17.8) n.s.a 81.9 (15.9) [27]
FACIT-Sp, mean (SD) 31.8 (8.4) 30.9 (8.9) n.s.a
HADS-D, mean (SD) 8.4 (1.7) 8.3 (1.7) n.s.a 6.2 (3.1) [28]
HADS-A, mean (SD) 9.8 (1.6) 10.0 (1.5) n.s.a 5.4 (4.6) [28]
MFI, mean (SD)
General fatigue 12.1 (2.7) 12.0 (3.2) n.s.a 12.1 (4.3) [29]
Physical fatigue 12.4 (5.2) 11.9 (5.3) n.s.a 11.8 (4.1) [29]
Reduced activity 12.2 (4.9) 12.1 (5.4) n.s.a 11.6 (4.4) [29]
Reduced motivation 8.9 (3.5) 9.3 (4.4) n.s.a 8.5 (3.4) [29]
Mental fatigue 10.4 (4.5) 9.8 (5.0) n.s.a 10.2 (4.6) [29]
at-test, one-sided.
HOM, homeopathy; FACT-G, Functional Assessment of Cancer
Therapy—General Scale; HADS-A, Hospital Anxiety and Depression Scale-
Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; SD,
standard deviation; n.s., not significant; FACIT-Sp, Functional Assessment
of Chronic Illness Therapy—Spiritual Scale; MFI, Multidimensional Fatigue
Inventory.
Table 6. Expectancies
HOM,
N = 250
Conventional
care, N = 310
P
values
I expect the treatment to .
have specific antitumor
effect (range: not at all
to very much), mean (SD)
3.5 (0.8) 3.6 (0.7) n.s.a
support the body in fighting
the disease (range:
not at all to very much),
mean (SD)
3.9 (0.4) 3.6 (0.7) 0.001a
enhance life expectancy
(range: not at all to very
much), mean (SD)
3.7 (0.7) 3.6 (0.7) n.s.a
enhance physical well-
being (range: not at all
to very much), mean (SD)
3.7 (0.6) 3.4 (0.9) 0.002a
enhance psychological
well-being (range: not at all
to very much), mean (SD)
3.5 (0.9) 3.1 (1.1) 0.000a
at-test, one-sided.
HOM, homeopathy; SD, standard deviation; n.s., not significant.
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different from patients recruited from conventional care
when entered into the study at the time point of starting
treatment.
We present data from the two groups of cancer patients: one
cohort was recruited in a homeopathic clinic in Switzerland
specialized in treating cancer patients and the other cohort was
recruited in a large oncology outpatient clinic. Both the groups
were recruited at the beginning of their respective treatments. It
can be seen from the results that there are some striking
similarities between the groups: both cohorts have low QoL and
high expectancies toward anticancer effects of treatment.
However, there are more relevant differences than similarities.
Cancer patients seeking homeopathy seem to start their
treatment at a much later phase during their course of disease
compared with patients beginning conventional treatment.
Moreover, in accordance with other studies, the patients in the
HOM cohort were 6 years younger, better educated and were
more likely to be employed compared with patients in the CC
cohort. The latter was not only due to the younger age but also
due to more patients from the HOM cohort being self-
employed (data not shown) and thus, they would be forced to
earn their income even during their cancer disease. With regard
to clinical variables, the HOM cohort consists of patients
presenting with slightly different cancer diagnoses (more
melanoma, less colorectal cancer). The most pronounced
differences were seen in the amount of imprecise tumor stages
in the HOM cohort. About a quarter of the patients were not
diagnosed according to state-of-the-art principles at the time
when the cancer was detected or their diagnostic results were
not available through the homeopathic clinic to verify the exact
tumor stage.
The course of the treatment following the cancer diagnosis
was also different regarding two aspects: the percentage of
patients who refused to be treated with conventional treatment
was much higher in the HOM cohort (in total 8%). However,
about half of the homeopathy patients had received
chemotherapy in the past, and 30% had undergone
radiotherapy when beginning homeopathic treatment, whereas
only 30% of the CC patients had already received
chemotherapy and 19% had had radiotherapy. This is
indicative of a different phase in the course of the disease:
whereas patients often seek homeopathy after the conventional
treatment is finished, patients in the CC group present to the
oncology clinic usually after surgery or after diagnosis of disease
progression.
It was obvious that there were relevant clinical differences
between these two groups of patients. However, it was
unexpected that the results regarding QoL scales and
measurements of emotional distress would be almost identical.
In another prospective observational study investigating the
benefit of homeopathy in a cohort of patients who were
referred to a British National Health Service homeopathic
hospital [7], 39% of the British cohort was in a metastatic state
compared with 52% in our sample. In our study as well as in
the British study, anxiety and depression scores (HADS) were
much higher than in a historical control group. Whereas in the
historical control group, anxiety was 6.2 and depression was 5.4
[27], patients who started treatment seem to be more stressed
[anxiety: 9.8 (HOM) and 10.0 (CC) in our study; 9.4 in the
British study and depression: 8.4 and 8.3, respectively, in our
study; 7.3 in the British study] irrespectively of HOM or CC
treatment. This is somewhat in accordance with other data
showing that depression predicts CAM use in breast cancer
patients [29] but explains only high scores in the cohort which
sought homeopathy. In our study also, the CC cohort showed
high anxiety and depression scores, probably due to different
reasons. Whereas the HOM cohort consists of patients having
a long disease history, the patients in the CC cohort seem to
suffer from the shock of being diagnosed (or tumor progress
being diagnosed).
Despite the long disease history and progressed tumor stage,
expectancies toward the benefit of homeopathy were quite high.
Since homeopathy is a medical system in its own right in
addition to conventional medicine, which is particularly sought
by patients who come to a specialized homeopathic clinic, these
differences cannot be generalized to other CAM treatments.
Hence, for research purposes, it is necessary to differentiate
between types of CAM treatment. If the research aim is
a comparison of whole-system CAM therapies (like
homeopathy) with conventional therapy, it is important to bear
the substantial differences in mind, especially when studying
the outcomes QoL and survival. QoL might be particularly
impaired due to adverse effects of conventional treatment when
patients turn to homeopathy. Survival data that is measured
starting from the point when cancer patients begin
homeopathic treatment is by no means comparable with the
data of cancer patients who begin conventional treatment as the
likelihood of having shorter survival periods clearly depends on
the disease status.
conclusions
We found that the initiation of homeopathy treatment in
cancer patients is likely to occur at a different phase during the
course of the disease compared with the start of conventional
treatment. Although both the groups of patients have very high
expectancies toward cure through either homeopathy or
conventional treatment and show comparable QoL measures
and measures of emotional distress, other important disease
variables are vastly different. Thus, when investigating
homeopathy in comparison with conventional treatment, it is
not useful to apply general designs like recruiting the control
group as well as the homeopathy group at the time of starting
treatment. It would be more advisable to recruit patients from
conventional care after defining specific criteria per patient
which match with criteria of a recruited homeopathy patient.
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